-
1
-
-
0016718612
-
Familial hyper-alpha-lipoproteinemia studies in eighteen kindreds
-
Glueck C.J., Fallat R.W., Millet F., Gartside P., Elston R.C., Go R.C. Familial hyper-alpha-lipoproteinemia studies in eighteen kindreds. Metabolism. 24:1975;1243-1265.
-
(1975)
Metabolism
, vol.24
, pp. 1243-1265
-
-
Glueck, C.J.1
Fallat, R.W.2
Millet, F.3
Gartside, P.4
Elston, R.C.5
Go, R.C.6
-
2
-
-
0024996141
-
Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis
-
Tall A.R. Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86:1990;379-384.
-
(1990)
J Clin Invest
, vol.86
, pp. 379-384
-
-
Tall, A.R.1
-
3
-
-
0030017590
-
Unravelling high-density lipoprotein-apolipoprotein metabolism in human mutants and animal models
-
Rader D.J., Ikewaki K. Unravelling high-density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol. 7:1996;117-123.
-
(1996)
Curr Opin Lipidol
, vol.7
, pp. 117-123
-
-
Rader, D.J.1
Ikewaki, K.2
-
4
-
-
0021508760
-
High-density lipoprotein metabolism
-
Eisenberg S. High-density lipoprotein metabolism. J Lipid Res. 25:1984;1017-1058.
-
(1984)
J Lipid Res
, vol.25
, pp. 1017-1058
-
-
Eisenberg, S.1
-
5
-
-
0032516013
-
The "best" of cholesterols, the "worst" of cholesterols. A tale of two receptors
-
Krieger M. The "best" of cholesterols, the "worst" of cholesterols. A tale of two receptors. Proc Natl Acad Sci USA. 95:1998;4077-4080.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 4077-4080
-
-
Krieger, M.1
-
6
-
-
0025322265
-
Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in the cholesterol-fed rabbit
-
Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 85:1990;1234-1241.
-
(1990)
J Clin Invest
, vol.85
, pp. 1234-1241
-
-
Badimon, J.J.1
Badimon, L.2
Fuster, V.3
-
7
-
-
0028839458
-
Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits
-
Miyazaki A., Sakuma S., Morikawa W., Takiue T., Miake F., Terano T., Sakai M., Hakamata H., Sakamoto Y.-I., Naito M., Ruan Y., Takahashi K., Ohta T., Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 15:1995;1882-1888.
-
(1995)
Arterioscler Thromb Vasc Biol
, vol.15
, pp. 1882-1888
-
-
Miyazaki, A.1
Sakuma, S.2
Morikawa, W.3
Takiue, T.4
Miake, F.5
Terano, T.6
Sakai, M.7
Hakamata, H.8
Sakamoto, Y.-I.9
Naito, M.10
Ruan, Y.11
Takahashi, K.12
Ohta, T.13
Horiuchi, S.14
-
8
-
-
0023001772
-
Fifteen-year mortality in Coronary Drug Project patients: Long-term benefit with niacin
-
Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedwald W. Fifteen-year mortality in Coronary Drug Project patients long-term benefit with niacin . J Am Coll Cardiol. 8:1986;1245-1255.
-
(1986)
J Am Coll Cardiol
, vol.8
, pp. 1245-1255
-
-
Canner, P.L.1
Berge, K.G.2
Wenger, N.K.3
Stamler, J.4
Friedman, L.5
Prineas, R.J.6
Friedwald, W.7
-
9
-
-
0023232216
-
Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
-
Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
-
(1987)
N Engl J Med
, vol.317
, pp. 1237-1245
-
-
Frick, M.H.1
Elo, O.2
Haapa, K.3
Heinonen, O.P.4
Heinsalmi, P.5
Helo, P.6
Huttunen, J.K.7
Kaitaniemi, P.8
Koskinen, P.9
Manninen, V.10
-
10
-
-
20244370323
-
Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)
-
Goldbourt U., Behar S., Reicher-Reiss H., Agmon J., Kaplinsky E., Graff E., Kishon Y., Caspi A., Weisbort J., Mandelzweig L., et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 71:1993;909-915.
-
(1993)
Am J Cardiol
, vol.71
, pp. 909-915
-
-
Goldbourt, U.1
Behar, S.2
Reicher-Reiss, H.3
Agmon, J.4
Kaplinsky, E.5
Graff, E.6
Kishon, Y.7
Caspi, A.8
Weisbort, J.9
Mandelzweig, L.10
-
11
-
-
0027386876
-
Rationale and Design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol
-
Rubins H.B., Robins S.J., Iwane M.K., Boden W.E., Elam M.B., Fye C.L., Gordon D.J., Schaefer E.J., Schectman G., Wittes J.T. Rationale and Design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 71:1993;45-52.
-
(1993)
Am J Cardiol
, vol.71
, pp. 45-52
-
-
Rubins, H.B.1
Robins, S.J.2
Iwane, M.K.3
Boden, W.E.4
Elam, M.B.5
Fye, C.L.6
Gordon, D.J.7
Schaefer, E.J.8
Schectman, G.9
Wittes, J.T.10
-
12
-
-
0344017724
-
Effects of estrogen or estrogen/progestin regimens on heart disease
-
Effects of estrogen or estrogen/progestin regimens on heart disease. Arch Intern Med. 153:1993;1528-1538.
-
(1993)
Arch Intern Med
, vol.153
, pp. 1528-1538
-
-
-
13
-
-
2042503551
-
Design and rationale for the Air Force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS)
-
Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A., Shapiro D.R., Langendorfer A., Gotto A.M. Jr. Design and rationale for the Air Force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS). Am J Cardiol. 80:1997;287-293.
-
(1997)
Am J Cardiol
, vol.80
, pp. 287-293
-
-
Downs, J.R.1
Beere, P.A.2
Whitney, E.3
Clearfield, M.4
Weis, S.5
Rochen, J.6
Stein, E.A.7
Shapiro, D.R.8
Langendorfer, A.9
Gotto A.M., Jr.10
-
14
-
-
0030808288
-
Pharmacology of apolipoprotein A-I
-
Andersson L.O. Pharmacology of apolipoprotein A-I. Curr Opin Lipidol. 8:1997;225-228.
-
(1997)
Curr Opin Lipidol
, vol.8
, pp. 225-228
-
-
Andersson, L.O.1
-
15
-
-
0029737826
-
Effects of intravenous infusion of lipid-free apo A-I in humans
-
Nanjee M.N., Crouse J.R., King J.M., Hovorka R., Rees S.E., Carson E.R., Morgenthaler J.J., Lerch P., Miller N.E. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol. 16:1996;1203-1214.
-
(1996)
Arterioscler Thromb Vasc Biol
, vol.16
, pp. 1203-1214
-
-
Nanjee, M.N.1
Crouse, J.R.2
King, J.M.3
Hovorka, R.4
Rees, S.E.5
Carson, E.R.6
Morgenthaler, J.J.7
Lerch, P.8
Miller, N.E.9
|